ATE398130T1 - Diaminopyrroloquinazoline als protein tyrosine phosphatase inhibitoren - Google Patents

Diaminopyrroloquinazoline als protein tyrosine phosphatase inhibitoren

Info

Publication number
ATE398130T1
ATE398130T1 AT04731898T AT04731898T ATE398130T1 AT E398130 T1 ATE398130 T1 AT E398130T1 AT 04731898 T AT04731898 T AT 04731898T AT 04731898 T AT04731898 T AT 04731898T AT E398130 T1 ATE398130 T1 AT E398130T1
Authority
AT
Austria
Prior art keywords
diaminopyrroloquinazoline
protein tyrosine
tyrosine phosphatase
phosphatase inhibitors
useful
Prior art date
Application number
AT04731898T
Other languages
English (en)
Inventor
Steven Berthel
Kshitij Thakkar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE398130T1 publication Critical patent/ATE398130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04731898T 2003-05-15 2004-05-10 Diaminopyrroloquinazoline als protein tyrosine phosphatase inhibitoren ATE398130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47078003P 2003-05-15 2003-05-15
US56276304P 2004-04-16 2004-04-16

Publications (1)

Publication Number Publication Date
ATE398130T1 true ATE398130T1 (de) 2008-07-15

Family

ID=33457197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04731898T ATE398130T1 (de) 2003-05-15 2004-05-10 Diaminopyrroloquinazoline als protein tyrosine phosphatase inhibitoren

Country Status (14)

Country Link
US (1) US7226915B2 (de)
EP (1) EP1633754B1 (de)
JP (1) JP4477010B2 (de)
KR (1) KR100755579B1 (de)
AT (1) ATE398130T1 (de)
AU (1) AU2004238515B2 (de)
BR (1) BRPI0410390A (de)
CA (1) CA2524709C (de)
DE (1) DE602004014370D1 (de)
ES (1) ES2309518T3 (de)
MX (1) MXPA05012208A (de)
PL (1) PL1633754T3 (de)
RU (1) RU2367664C2 (de)
WO (1) WO2004101569A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262297B2 (en) * 2003-05-15 2007-08-28 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7322412B2 (en) * 2004-08-30 2008-01-29 Halliburton Energy Services, Inc. Casing shoes and methods of reverse-circulation cementing of casing
WO2011153310A1 (en) 2010-06-02 2011-12-08 Trius Therapeutics Dihydrofolate reductase inhibitors
EP4630001A1 (de) * 2022-12-05 2025-10-15 Merck Sharp & Dohme LLC Substituierte chinazolinderivate und verfahren zur verwendung davon
WO2025253326A1 (ko) * 2024-06-05 2025-12-11 에스케이바이오팜 주식회사 Kras 저해제로서 신규한 3환 화합물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118561A (en) * 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
US4208520A (en) * 1978-06-28 1980-06-17 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
US4233445A (en) * 1979-07-05 1980-11-11 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3.2-F]-quinazoline-1,3-diamines
US4288595A (en) * 1980-04-24 1981-09-08 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
PL171914B1 (pl) * 1991-03-28 1997-06-30 Eisai Co Ltd Sposób wytwarzania pochodnych aminy heterocyklicznej PL PL PL PL PL PL PL
GB9123916D0 (en) 1991-11-11 1992-01-02 Wellcome Found Heterocyclic compounds
EP1077968A1 (de) 1998-05-12 2001-02-28 American Home Products Corporation Naphto[2,3-b]heteroar-4-yl-derivate
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物

Also Published As

Publication number Publication date
US20040229890A1 (en) 2004-11-18
AU2004238515B2 (en) 2008-01-24
WO2004101569A1 (en) 2004-11-25
JP2006528945A (ja) 2006-12-28
RU2367664C2 (ru) 2009-09-20
KR20060011874A (ko) 2006-02-03
DE602004014370D1 (de) 2008-07-24
PL1633754T3 (pl) 2008-11-28
AU2004238515A1 (en) 2004-11-25
US7226915B2 (en) 2007-06-05
EP1633754B1 (de) 2008-06-11
MXPA05012208A (es) 2006-02-08
KR100755579B1 (ko) 2007-09-06
ES2309518T3 (es) 2008-12-16
CA2524709C (en) 2009-09-15
CA2524709A1 (en) 2004-11-25
BRPI0410390A (pt) 2006-07-18
RU2005138895A (ru) 2007-06-27
JP4477010B2 (ja) 2010-06-09
EP1633754A1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
BRPI0606379A2 (pt) triazolftalazinas
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
NO20060091L (no) Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EP2037922A4 (de) Prolyl-hydroxylase-hemmer
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
MEP52808A (en) Aminoheteroaryl compounds as protein kinase inhibitors
EA201070140A1 (ru) Композиции 24-с-метилтрансферазы стерина leishmania для профилактики, лечения и диагностики лейшманиоза
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
EP2133342A4 (de) Inhibitor von proteinthyrosinphosphatase 1b, herstellungsverfahren und anwendungen davon
EA201071221A1 (ru) Гетероциклические соединения
UY27606A1 (es) Inhibidores de la fosfarasa
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
NO20075227L (no) Treatment of eczemas
DE602004014370D1 (de) Diaminopyrroloquinazoline als protein tyrosine phosphatase inhibitoren
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
WO2008070552A3 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1633754

Country of ref document: EP